Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of error-prone translesion synthesis. [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:22761594]
Positive regulation of error-prone translesion synthesis (TLS) is a complex cellular process that ensures DNA replication can continue despite the presence of DNA damage. This process involves specialized DNA polymerases that can bypass lesions that block the progression of the replicative DNA polymerases. However, these TLS polymerases often lack proofreading activity, leading to the introduction of mutations. This can be beneficial in some contexts, as it allows cells to bypass potentially lethal lesions, but it also poses a risk of introducing mutations that can lead to cancer.
The regulation of TLS is tightly controlled to ensure that it only occurs when necessary and to minimize the potential for mutagenesis. One key regulatory mechanism involves the recruitment of TLS polymerases to the site of DNA damage. This recruitment is mediated by a variety of factors, including PCNA (proliferating cell nuclear antigen) and specialized adaptor proteins. PCNA, a ring-shaped protein that encircles DNA, serves as a platform for the assembly of various proteins involved in DNA replication, including DNA polymerases. Damage recognition proteins, such as RAD6 and RAD18, are recruited to the site of DNA damage and modify PCNA through ubiquitination. This modification serves as a signal to recruit TLS polymerases to the damaged site.
Another level of regulation involves the activation of TLS polymerases. This can be achieved by various mechanisms, including phosphorylation and conformational changes. For example, ATR (ataxia telangiectasia mutated and Rad3-related) kinase, which is activated in response to DNA damage, phosphorylates the TLS polymerase REV1. This phosphorylation event promotes the recruitment of REV1 to the site of damage and facilitates its interaction with other TLS polymerases.
Finally, the termination of TLS is also tightly controlled. After the TLS polymerase has bypassed the lesion, the replicative polymerase must resume replication. This process involves the removal of the TLS polymerase and the replacement with the replicative polymerase. This switch is facilitated by a variety of factors, including PCNA ubiquitination status and the presence of specific DNA sequences.
In summary, the positive regulation of error-prone translesion synthesis is a multi-faceted process that involves the recruitment, activation, and termination of TLS polymerases. This complex regulatory network ensures that TLS is only activated when necessary and that it does not introduce an excessive number of mutations.'
"
Protein | Definition | Taxonomy |
---|---|---|
Ubiquitin carboxyl-terminal hydrolase 1 | A ubiquitin carboxyl-terminal hydrolase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O94782] | Homo sapiens (human) |
Ubiquitin carboxyl-terminal hydrolase 1 | A ubiquitin carboxyl-terminal hydrolase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O94782] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
trifluoperazine | N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines | antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug | |
pimozide | pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) | benzimidazoles; heteroarylpiperidine; organofluorine compound | antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist |
nih-12848 | NIH-12848: inhibits phosphatidylinositol 5-phosphate 4-kinase gamma; structure in first source | ||
gw 7647 | GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group. GW 7647: a PPAR-alpha agonist; structure in first source | aryl sulfide; monocarboxylic acid; ureas | PPARalpha agonist |
rottlerin | rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1); | aromatic ketone; benzenetriol; chromenol; enone; methyl ketone | anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite |
flupenthixol | cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration. | flupenthixol | dopaminergic antagonist |